Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.75 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.75 |
| ▸ | JUN | P05412 | 4/20 | 0.70 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tylophorine SCHEMBL31497488 | 1.00 | HIF1A (0.75) | HIF1AEPAS1JUNEHMT2DRD1 | |
| (S)-Tylophorine SCHEMBL523625 | 1.00 | HIF1A (0.75) | HIF1AEPAS1JUNEHMT2DRD1 | |
| (+/-)-Tylophorine SCHEMBL523626 | 1.00 | HIF1A (0.75) | HIF1AEPAS1JUNEHMT2DRD1 | |
| Tylophorine SCHEMBL30193979 | 1.00 | HIF1A (0.75) | HIF1AEPAS1JUNEHMT2DRD1 | |
| (S)-Tylophorine SCHEMBL30116767 | 1.00 | HIF1A (0.75) | HIF1AEPAS1JUNEHMT2DRD1 | |
| (S)-Tylophorine SCHEMBL5610438 | 0.99 | HIF1A (0.73) | HIF1AEPAS1JUNEHMT2 | |
| SCHEMBL13222745 | 0.96 | HIF1A (0.81) | HIF1AEPAS1JUNEHMT2 | |
| SCHEMBL30637462 | 0.96 | HIF1A (0.81) | HIF1AEPAS1JUNEHMT2 | |
| SCHEMBL13222766 | 0.94 | HIF1A (0.80) | HIF1AEPAS1JUNEHMT2 | |
| SCHEMBL13222824 | 0.93 | JUN (0.81) | HIF1AEPAS1JUNDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708310-B2 | Phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof, preparation method and use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2017-07-18 | — | — | US | disclosed |
| US-20170152257-A1 | PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE ALKALOID HAVING A HYDROXYL GROUP ON THE PHENANTHRENE RING THEREOF, PREPARATION METHOD AND USE THEREOF | CHINA MEDICAL UNIVERSITY (TW) | 2017-06-01 | — | — | US | disclosed |
| US-9216977-B2 | Antofine and cryptopleurine derivatives as anticancer agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-12-22 | — | — | US | disclosed |
| US-9174979-B2 | Phenanthroindolizidine compound and NFκB inhibitor containing same as active ingredient | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2015-11-03 | — | — | US | disclosed |
| EP-2351754-B1 | PHENANTHROINDOLIZIDINE COMPOUND AND NF kB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | YAKULT HONSHA KK (JP) | 2015-06-24 | — | — | EP | disclosed |
| EP-2351753-B1 | PHENANTHROINDOLIZIDINE DERIVATIVE AND NF kB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | YAKULT HONSHA KK (JP) | 2015-02-11 | — | — | EP | disclosed |
| US-8569327-B2 | Phenanthroindolizidine derivative and NFκB inhibitor containing same as active ingredient | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2013-10-29 | — | — | US | disclosed |
| US-20120283220-A1 | ANTOFINE AND CRYPTOPLEURINE DERIVATIVES AS ANTICANCER AGENTS | NIH-DEITR | 2012-11-08 | — | — | US | disclosed |
| US-8188089-B2 | Tylophorine analogs as antitumor agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110201637-A1 | PHENANTHROINDOLIZIDINE DERIVATIVE AND NFKB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2011-08-18 | — | — | US | disclosed |
| US-20110201638-A1 | PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-2351753-A1 | PHENANTHROINDOLIZIDINE DERIVATIVE AND NF B INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | Kabushiki Kaisha Yakult Honsha (JP) | 2011-08-03 | — | — | EP | disclosed |
| EP-2351754-A1 | PHENANTHROINDOLIZIDINE COMPOUND AND NF B INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | Kabushiki Kaisha Yakult Honsha (JP) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011049704-A1 | ANTOFINE AND CRYPTOPLEURINE DERIVATIVES AS ANTICANCER AGENTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2010047126-A1 | PHENANTHROINDOLIZIDINE DERIVATIVE AND NFκB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | 株式会社ヤクルト本社 (JP) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010047127-A1 | PHENANTHROINDOLIZIDINE COMPOUND AND NFκB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | 株式会社ヤクルト本社 (JP) | 2010-04-29 | — | — | WO | disclosed |
| US-20080300254-A1 | Tylophorine Analogs as Antitumor Agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152257-A1 | PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE ALKALOID HAVING A HYDROXYL GROUP ON THE PHENANTHRENE RING THEREOF, PREPARATION METHOD AND USE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAH, HIPK4 | HIF1A 487/4885EPAS1 592/4885JUN 2252/4885 |
| US-20110201638-A1 | PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | NFKBIA, NFKB2, NFKB1 | HIF1A 1332/4885EPAS1 2353/4885JUN 118/4885 |
| US-20120283220-A1 | ANTOFINE AND CRYPTOPLEURINE DERIVATIVES AS ANTICANCER AGENTS | XPO5, TYMP, CA5A | HIF1A 1409/4885EPAS1 2295/4885JUN 4522/4885 |
| US-20080300254-A1 | Tylophorine Analogs as Antitumor Agents | RPL30, RPL18A, RPP30 | HIF1A 3670/4885EPAS1 4609/4885JUN 4504/4885 |
| US-20110201637-A1 | PHENANTHROINDOLIZIDINE DERIVATIVE AND NFKB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | NFKBIA, NFKB2, NFKB1 | HIF1A 1335/4885EPAS1 2130/4885JUN 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.